Pensabio will distribute Illumina's next-generation sequencing platforms and products in the country.
Through targeted sequencing on tumors from several biliary tract subtypes, researchers are uncovering mutations of potential treatment or prognostic relevance.
Researchers presenting at ASCO demonstrated the 100-gene panel test plus targeted therapy leads to better outcomes and lower cost than standard chemotherapy.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
Leerink gave the firm an "Outperform" rating with an $18 price target while Canaccord gave it a "Buy" rating with a $17 price target.
In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.
A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.
As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.
This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.